We have reapplied to the Defense Innovation Accelerator for the North Atlantic (DIANA) for our innovative synthetic blood substitute respirocyte project.

This year – unlike in previous years – blood substitutes were explicitly identified as an area of interest in the DIANA funding call criteria. This is a clear confirmation of the strategic importance of our technology at the international level.

NanoGroup’s respirocytes eliminate the key challenges of traditional transfusions: they do not require matching to a blood group, have a significantly longer shelf life under normal conditions, and eliminate the risk of infectious disease transmission. Their characteristics are ideally suited to the requirements of the modern battlefield.

Participation in the DIANA program is an opportunity for us to accelerate research and establish contacts in the defense field. The goal of the gas pedal is to strengthen NATO’s technological edge by reducing barriers to entry into the sector for innovative companies from member countries.

The current edition is expected to be resolved in the fall.

#StayNanoTuned!